Richard T Silver

List of Publications by Citations

146 papers	8,626 citations	33 h-index	92 g-index
156 ext. papers	9,725 ext. citations	3.6 avg, IF	5.36 L-index

#	Paper	IF	Citations
146	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*, **2013**, 122, 872-84	2.2	1413
145	Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *Journal of Clinical Oncology*, **2009**, 27, 6041-51	2.2	1019
144	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. *Blood*, **2002**, 99, 1928-37	2.2	850
143	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. *Blood*, **2005**, 106, 2162-8	2.2	706
142	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *Journal of Clinical Oncology*, **2011**, 29, 761-70	2.2	589
141	Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults. *Blood*, **1968**, 32, 507-523	2.2	441
140	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). *Blood*, **2006**, 108, 1497-503	2.2	287
139	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. *Leukemia*, **2018**, 32, 1057-1069	10.7	263
138	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. *Journal of Hematology and Oncology*, **2017**, 10, 55	22.4	208
137	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. *Haematologica*, **2015**, 100, 479-88	6.6	174
136	Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid Leukemia. *Blood*, **1998**, 91, 3357-3365	2.2	153
135	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Haematology,the*, **2017**, 4, e317-e324	14.6	148
134	The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. *Blood*, **2008**, 112, 231-9	2.2	137
133	Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. *Cancer*, **1992**, 70, 2214-24	6.4	128
132	Characteristics of the Terminal Phase of Chronic Granulocytic Leukemia. *Blood*, **1968**, 32, 445-459	2.2	122
131	Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. *Cancer*, **2006**, 107, 451-8	6.4	116
130	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. *Blood*, **2006**, 107, 3339-41	2.2	107

129	Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. *Blood*, **2011**, 117, 6669-72	2.2	104
128	Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. *Expert Review of Hematology*, **2013**, 6, 49-58	2.8	81
127	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. *Blood*, **2019**, 134, 1498-1509	2.2	80
126	Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. *Blood*, **2013**, 122, 1881-6	2.2	80
125	A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia. *Blood*, **1998**, 92, 2315-2321	2.2	66
124	Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. *Cancer*, **1980**, 45, 232-5	6.4	64
123	Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. *Journal of Molecular Diagnostics*, **2007**, 9, 272-6	5.1	54
122	Management of chronic myeloid leukemia in blast crisis. *Annals of Hematology*, **2015**, 94 Suppl 2, S159-65	3	52
121	Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. *Journal of Clinical Oncology*, **2000**, 18, 1301-8	2.2	49
120	JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. *Leukemia Research*, **2011**, 35, 177-82	2.7	48
119	Interferon-alpha 2b: a new treatment for polycythemia vera. *Annals of Internal Medicine*, **1993**, 119, 1091-82	2	48
118	Management of CML-blast crisis. *Best Practice and Research in Clinical Haematology*, **2016**, 29, 295-307	4.2	47
117	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. *American Journal of Hematology*, **2020**, 95, 594-603	7.1	45
116	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials.. *Blood*, **2004**, 104, 23-23	2.2	39
115	Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. *Modern Pathology*, **2015**, 28, 1315-23	9.8	37
114	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. *Blood*, **2018**, 132, 686-686	2.2	33
113	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). *Blood*, **2018**, 132, 577-577	2.2	32
112	The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. *Cancer*, **2017**, 123, 2680-2687	6.4	31

111	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. *Blood*, **2014**, 124, 713-713	2.2	29
110	JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. *Haematologica*, **2013**, 98, e135-7	6.6	27
109	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. *Blood*, **2015**, 126, 56-56	2.2	27
108	Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. *Haematologica*, **2012**, 97, 538-42	6.6	26
107	Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. *Blood*, **2016**, 127, 1398-402	2.2	26
106	Use of Testosterone and Busulfan in the Treatment of Myelofibrosis with Myeloid Metaplasia. *Blood*, **1964**, 23, 341-353	2.2	25
105	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. *American Journal of Hematology*, **2017**, 92, 1062-1067	7.1	23
104	The blast phase of chronic myeloid leukaemia. *Best Practice and Research in Clinical Haematology*, **2009**, 22, 387-94	4.2	21
103	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. *Haematologica*, **2018**, 103, e392-e394	6.6	20
102	Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. *Cancer Genetics and Cytogenetics*, **2002**, 137, 79-84		20
101	The Importance of Bone Marrow Biopsy in the Staging of Patients With Lymphosarcoma. *Blood*, **1973**, 41, 913-920	2.2	20
100	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. *Blood*, **2016**, 128, 479-479	2.2	20
99	Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. *Journal of Clinical Oncology*, **2011**, 29, e564-5	2.2	19
98	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. *Leukemia*, **2021**, 35, 2592-2601	10.7	19
97	Ruxolitinib for myelofibrosis--an update of its clinical effects. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 638-45	2	18
96	Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia. *British Journal of Haematology*, **2010**, 151, 288-91	4.5	18
95	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. *Blood*, **2013**, 122, 396-396	2.2	18
94	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. *JAMA Oncology*, **2021**, 7, 42-50	13.4	16

93	Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. *Leukemia and Lymphoma*, **2003**, 44, 39-48	1.9	14
92	High dose methotrexate with citrovorum factor in adult resistant lymphoma. *Cancer*, **1977**, 40, 2823-8	6.4	14
91	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). *Blood*, **2013**, 122, 661-661	2.2	13
90	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. *BMC Cancer*, **2018**, 18, 359	4.8	11
89	Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?. *Expert Review of Hematology*, **2015**, 8, 439-45	2.8	11
88	Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10, 331-5	2	11
87	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. *Cancer Medicine*, **2019**, 8, 4089-4092	4.8	10
86	Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. *Hematology*, **2016**, 21, 387-91	2.2	10
85	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. *Haematologica*, **2013**, 98, 1421-3	6.6	10
84	Chronic myeloid leukemia. *Hematology/Oncology Clinics of North America*, **2003**, 17, 1159-73, vi-vii	3.1	10
83	A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera. *Blood*, **2008**, 112, 2810-2810	2.2	10
82	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 297-303	2	10
81	The hematocrit value in polycythemia vera: caveat utilitor. *Leukemia and Lymphoma*, **2015**, 56, 1540-1	1.9	9
80	Treatment of polycythemia vera with imatinib mesylate. *Leukemia Research*, **2012**, 36, 156-62	2.7	9
79	Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma. *Medical and Pediatric Oncology*, **1994**, 22, 228-35		9
78	Ruxolitinib Discontinuation In Patients With Myelofibrosis: An Analysis From Clinical Practice. *Blood*, **2013**, 122, 2833-2833	2.2	9
77	Distinguishing essential thrombocythemia V617F from polycythemia vera: limitations of erythrocyte values. *Haematologica*, **2019**, 104, 2200-2205	6.6	8
76	A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. *Cancer*, **1987**, 60, 1442-8	6.4	8

75	Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. *Blood*, **2011**, 118, 278-278	2.2	8
74	Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. *Blood*, **2012**, 120, 800-800	2.2	8
73	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. *HemaSphere*, **2021**, 5, e562	0.3	8
72	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. *Blood Cancer Journal*, **2018**, 8, 89	7	8
71	Treatment of polycythemia vera. *Seminars in Thrombosis and Hemostasis*, **2006**, 32, 437-42	5.3	7
70	Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon □treated polycythemia vera patients. *Haematologica*, **2017**, 102, e97-e99	6.6	6
69	Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. *Journal of the American Society of Echocardiography* , **2019**, 32, 1574-1585	5.8	6
68	HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification. *Cancer*, **1985**, 55, 2342-7	6.4	6
67	Unusual translocations involving chromosomes 12;22 and 9;12 in a case of chronic myelogenous leukemia. *Cancer Genetics and Cytogenetics*, **1985**, 14, 61-5		6
66	A Randomized, Phase 3, Trial of Interferon-□versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.. *Blood*, **2022**,	2.2	6
65	Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50□100x109/L.. *Journal of Clinical Oncology*, **2012**, 30, 6630-6630	2.2	6
64	Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.. *Journal of Clinical Oncology*, **2019**, 37, 7057-7057	2.2	6
63	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.. *Lancet Haematology,the*, **2022**, 9, e301-e311	14.6	6
62	Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. *Leukemia and Lymphoma*, **2017**, 58, 2768-2769	1.9	5
61	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. *Leukemia Research*, **2018**, 69, 100-102	2.7	5
60	Recombinant gamma-interferon has activity in chronic myeloid leukemia. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1990**, 13, 49-54	2.7	5
59	Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients. *Medical and Pediatric Oncology*, **1984**, 12, 17-24		5
58	Platelet Amino Acid Levels in Essential Thrombocytosis. *Blood*, **1966**, 27, 715-721	2.2	5

57	Imatinib Mesylate (GLEEVEC) Is Effective in the Treatment of Polycythemia Vera: A Multi-Institutional Clinical Trial.. *Blood*, **2004**, 104, 656-656	2.2	5
56	Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis. *Blood*, **2013**, 122, 4053-4053	2.2	5
55	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. *Blood*, **2014**, 124, 738-738	2.2	5
54	Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. *Psychophysiology*, **2005**, 4, 235-7		5
53	Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). *International Journal of Cancer*, **1988**, 41, 829-31	7.5	4
52	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. *Blood*, **2016**, 128, 4271-4271	2.2	4
51	Are all interferons the same for therapy in polycythemia vera?. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13 Suppl 2, S305-6	2	3
50	The treatment of essential thromobocytosis revisited. *Blood*, **2011**, 118, 1179-80; author reply 1180-1	2.2	3
49	Administration of a complex chemotherapy regimen: inpatient versus outpatient treatment. *Medical and Pediatric Oncology*, **1983**, 11, 333-5		3
48	The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFN) Treatment in Early Myelofibrosis. *Blood*, **2016**, 128, 944-944	2.2	3
47	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. *American Journal of Hematology*, **2020**, 95, E1-E3	7.1	3
46	Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib. *Clinical Case Reports (discontinued)*, **2021**, 9, 2228-2235	0.7	3
45	Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. *Current Hematologic Malignancy Reports*, **2007**, 2, 43-6	4.4	2
44	The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. *Medical and Pediatric Oncology*, **1975**, 1, 207-16		2
43	Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study. *Medical and Pediatric Oncology*, **1979**, 6, 23-38		2
42	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. *Blood*, **2019**, 134, 4165-4165	2.2	2
41	JAK2 V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity.. *Blood*, **2007**, 110, 2530-2530	2.2	2
40	Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,. *Blood*, **2011**, 118, 3842-3842	2.2	2

39	Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. *Blood*, **2014**, 124, 1811-1811	2.2	2
38	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). *Blood*, **2014**, 124, 1826-1826	2.2	2
37	Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy.. *Journal of Clinical Oncology*, **2012**, 30, 6624-6624	2.2	2
36	Chronic Myeloid Leukemia **2016**, 1-11		2
35	Life, genes, and death in Ph- MPNs. *Blood*, **2014**, 124, 2471-2	2.2	1
34	Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-□A Cancer and Leukemia Group B study **2004**, 25, 143		1
33	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. *Blood*, **2020**, 136, 31-32	2.2	1
32	The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations.. *Blood*, **2009**, 114, 433-433	2.2	1
31	Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera,. *Blood*, **2011**, 118, 3837-3837	2.2	1
30	Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I). *Blood*, **2011**, 118, 5146-5146	2.2	1
29	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. *Blood*, **2014**, 124, 1824-1824	2.2	1
28	Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.. *Journal of Clinical Oncology*, **2014**, 32, 7114-7114	2.2	1
27	Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.. *Journal of Clinical Oncology*, **2016**, 34, 7012-7012	2.2	1
26	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for JAK2 V617F Myeloproliferative Neoplasms (MPNs). *Blood*, **2021**, 138, 627-627	2.2	1
25	Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. *Blood*, **2019**, 134, 705-705	2.2	1
24	Recombinant Interferon Alpha (rIFN□May Retard Progression of Early Primary Myelofibrosis (PM) by Reducing Splenomegaly and by Changing Marrow Morphology.. *Blood*, **2008**, 112, 1758-1758	2.2	1
23	Normal Life Expectancy for Polycythemia Vera Patients Is Possible. *Blood*, **2021**, 138, 2575-2575	2.2	0
22	Myelofibrosis: best practices, controversies and 2019 update. *Expert Review of Hematology*, **2020**, 13, 71-84	2.8	0

21	Excess mortality in younger patients with myeloproliferative neoplasms.. *Leukemia and Lymphoma*, **2022**, 1-5	1.9	0
20	Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?. *Oncologist*, **2011**, 16, 554-8	5.7	
19	The ABCCs of myelofibrosis. *Blood*, **2005**, 106, 2598-2599	2.2	
18	Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials. *Blood*, **2020**, 136, 19-21	2.2	
17	Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectivnes of Imatinib : Studies from a Multi-Institutional Trial.. *Blood*, **2004**, 104, 2431-2431	2.2	
16	No Significant Molecular Response in Polycythemia Vera Patients Treated with Imatinib or Interferon alpha.. *Blood*, **2005**, 106, 373-373	2.2	
15	Chronic Myeloid Leukemia (CML): A Model Disease for Utilizing Evidence Based Guidelines in a Decade of Progress.. *Blood*, **2006**, 108, 3313-3313	2.2	
14	Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes.. *Blood*, **2006**, 108, 4914-4914	2.2	
13	JAK2 Mutations Are Present in All Cases of Polycythemia Vera.. *Blood*, **2007**, 110, 4669-4669	2.2	
12	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. *Blood*, **2019**, 134, 2207-2207	2.2	
11	Evaluation of Bone Marrowmmorphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. *Blood*, **2016**, 128, 5471-5471	2.2	
10	Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype. *Blood*, **2008**, 112, 173-173	2.2	
9	Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.. *Blood*, **2009**, 114, 2917-2917	2.2	
8	A Novel in Vitro Model of Focal Fibrosis in Bone Marrow Stromal Co-Culture of CD34+ Cells From Patients with Idiopathic Myelofibrosis.. *Blood*, **2009**, 114, 2896-2896	2.2	
7	Jumping Translocations of the Long Arms of Chromosome 1 (1qJT) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML).. *Blood*, **2009**, 114, 1567-1567	2.2	
6	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. *Blood*, **2010**, 116, 2348-2348	2.2	
5	In Vivo Imaging of Cerebral Circulation In Mouse Models of Polycythemia Vera. *Blood*, **2010**, 116, 4091-4091	2.2	
4	Monocytes Modulate Megakaryocyte-Mediated Fibrosis of Bone Marrow Stromal Cells in Vitro. *Blood*, **2012**, 120, 1759-1759	2.2	

3	Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs. *Blood*, **2012**, 120, 5068-5068	2.2
2	CML End Phase and Blast Crisis: Implications and Management. *Hematologic Malignancies*, **2021**, 179-196	0
1	Current treatment of myelofibrosis. *Clinical Advances in Hematology and Oncology*, **2005**, 3, 269-70	0.6